Fellowship · Little Rock, AR
Sponsored by University of Arkansas for Medical Sciences (UAMS) College of Medicine
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
The New England journal of medicine · 2024 · 1,637 citations · Sam Moussa
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
Nature medicine · 2023 · 359 citations · Sam Moussa
AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders.
Gastroenterology · 2024 · 105 citations · Gaurav Syal
Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts.
Gastroenterology · 2023 · 160 citations · Sumant Inamdar
Life's Essential 8 and the risk of cardiovascular disease: a systematic review and meta-analysis.
European journal of preventive cardiology · 2025 · 59 citations · Yash Shah
A Scoping Review on Adverse Childhood Experiences Studies Using Latent Class Analysis: Strengths and Challenges.
Trauma, violence & abuse · 2024 · 47 citations · Ryan Heath
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Gastroenterology · 2021 · 230 citations · Sam Moussa
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
Hepatology communications · 2021 · 160 citations · Sam Moussa